INTRODUCTION
Antibiotic-associated diarrhoea (AAD) is defined as an acute inflammation of the intestinal mucosa caused by the administration of broad-spectrum antibiotics. The bacterial agent most commonly associated with AAD is Clostridium difficile.
1 However, when the normal faecal
Gram-negative organisms are absent, overgrowth by staphylococci, yeasts and fungi has been implicated. 2 The frequency of AAD depends on the definition of diarrhoea, the inciting antimicrobial agents and host factors. Almost all antibiotics, particularly those that act on anaerobes, can cause diarrhoea, but the risk is higher with aminopenicillins, a combination of aminopenicillins and clavulanate, cephalosporins and clindamycin. 3, 4 AAD occurs in approximately 5-30% of patients between the initiation of therapy and up to 2 months after the end of treatment. 1, 5, 6 The incidence of diarrhoea in children receiving broad-spectrum antibiotics ranges from 11 to 40%. 7, 8 Measures to prevent AAD include the use of probiotics, which are live microbial food ingredients that are beneficial to health. 9 Well-known probiotics include lactobacilli, bifidobacteria and the yeast Saccharomyces boulardii. The rationale for the use of probiotics in AAD is based on the assumption that the key factor in the pathogenesis of AAD is a disturbance in normal intestinal microflora. 10 Studies have established the effectiveness of S. boulardii in the prevention of AAD in adults. A recent metaanalysis of four randomized-controlled trials (RCTs) [11] [12] [13] [14] involving 688 adults showed that compared with placebo, S. boulardii was associated with a statistically significant decrease in the incidence of AAD (odds ratio 0.39; 95% CI: 0.25-0.62). 15 However, it is unclear whether similar benefits occur in children, as the only published trial involving children was neither randomized nor blinded. 16 Furthermore, conflicting data about the effects of another probiotic, Lactobacillus rhamnosus GG, suggest a different response in adult 17 and paediatric populations 18, 19 and that results observed in one population cannot be simply extrapolated to the other. Therefore, our study was designed to assess the effectiveness of S. boulardii in preventing AAD in children requiring antibiotic treatment for otitis media and/or respiratory tract infection.
PATIENTS AND METHODS

Study design
This was a double-blind, randomized, placebo-controlled clinical trial intended to evaluate the efficacy, safety and tolerability of S. boulardii in the prevention of AAD in children.
Randomization
Investigators at the Medical University of Warsaw used computers to generate independent allocation sequences and randomization lists for each study site.
To avoid a disproportionate number of patients in the experimental or placebo group, randomization at each site was performed in blocks of six (three received placebo and three, active treatment). To ensure allocation concealment, an independent subject prepared the randomization schedule and oversaw the packaging and labelling of trial treatments. All investigators, participants, outcome assessors and data analysts were blinded to the assigned treatment throughout the study.
Participants
The study was conducted between Each patient (or a parent, in the case of very young patients) received a diary to record the frequency of daily bowel movements, as well as any symptoms they considered important. Stool number and consistency were recorded daily. In the event of loose or watery stools, patients were advised to contact their doctors and bring stool samples for analysis. The presence of rotavirus-antigen was investigated in all diarrhoeal stool samples using a commercial latex agglutination test with a rotavirus-specific monoclonal antibody (Slidex Rota-Kit 2; BioMerieux, Lyon, France). Standard stool cultures were used to screen for bacteria (Salmonella, Shigella), and C. difficile toxins A and B were identified by enzyme immunoassay (C. difficile TOX A/B Test, TechLab Inc., Blacksburg, VA, USA).
Treatment compliance was assessed by direct interview of the patient (or parent) and review of the diary cards (which documented the number of daily wafers taken).
Treatment responses also were assessed by evaluation of the daily diaries.
Outcome measures
The 'primary' outcome measures were the frequencies of diarrhoea and AAD. Diarrhoea was defined as ‡3 loose or watery stools per day for a minimum of 48 h, occurring during and/or up to 2 weeks after the end of the antibiotic therapy. AAD was diagnosed in cases of diarrhoea, defined clinically as above, caused by C. difficile (the major enteropathogen in AAD) 1 or for otherwise unexplained diarrhoea (i.e. negative laboratory stool test for rotavirus and negative stool culture). The 'secondary' outcome measures were the frequencies of rotaviral diarrhoea, Salmonella diarrhoea, Shigella diarrhoea and C. difficile diarrhoea; the need for discontinuation of the antibiotic treatment, hospitalization to manage the diarrhoea (in out-patients), or intravenous rehydration in any of the study groups; and adverse events.
Sample size
We assumed that the study withdrawal rate would be at least 20% and that the probability of an episode of AAD occurring in the control group would be equal to 0.25 (25%). Based on this, we estimated that a minimum sample size of 135 children in each treatment group would show, with a 5% level of significance and a power of 80%, a 10% reduction in the proportion of children with AAD in the intervention groups (Fisher exact test).
Statistical analysis
The Student's t-test was used to compare mean values of continuous variables approximating a normal distribution. For non-normally distributed variables, the Mann-Whitney U-test was used. The chi-square test or Fisher exact test was used, as appropriate, to compare percentages. The relative risk (RR), 95% confidence interval (CI), and number needed to treat (NNT) were calculated using the same computer software. The difference between study groups was considered significant when the P-value was <0.05 or when the 95% CI for RR did not exceed 1.0 (equivalent to P < 0.05). Statistical analysis was performed using the computer software STATDIRECT 1,9,12 [(2002-05011) : Iain E.
Buchan]. All statistical tests were two tailed and performed at the 5% level of significance.
We report the analysis based on allocated treatment, i.e. all of the participants in a trial for which outcome data were available were analysed according to the intervention to which they were assigned, whether or not they received it. A potential problem with this type of analysis is that, unless the absence of an observation is independent of outcome, missing responses can lead to bias. Therefore, for both primary outcome measures, we also investigated the effect of various methods of handling missing responses in a trial. 21 That is, we compared outcomes in both treatment groups (S. boulardii vs. placebo) assuming: (i) all patients in both groups with an unknown outcome to have had either a good or a poor outcome, (ii) extreme case favouring of S boulardi and (iii) extreme case favouring of placebo.
Ethical considerations
Parents were fully informed about the aims of the study, and informed consent was obtained from at least one parent. The study protocol was reviewed and approved by the ethical review committee. enrolled in the study, 132 received S. boulardii and 137 received placebo. Overall, 23 (8.6%) of the randomized children [13 (9.8%) in the S. boulardii group and 10 (7.2%) in the placebo group] withdrew before completing the trial and were lost to follow-up. The reasons for not completing the trial were non-acceptance of the allocated intervention (n ¼ 22) or damage of the study product (n ¼ 1) (Figure 1 ). Thus, of the 269 children enrolled, 246 (91.4%) were available for the analyses (experimental group, n ¼ 119; placebo group, n ¼ 127). Baseline demographic and clinical characteristics did not significantly differ between the two groups ( Table 1) . The outcome measures are summarized in Table 2 5-15) children would need to be treated with S. boulardii to prevent a single episode of AAD. The risk of documented C. difficile diarrhoea was also lower in the S. boulardii group compared with the placebo group, but the difference was of borderline significance (RR 0.3, 95% CI: 0.1-1.04). There was no need for discontinuation of antibiotic treatment, hospital treatment because of diarrhoea in the out-patients, or intravenous rehydration in any of the study groups. The S. boulardii was well-tolerated, and no adverse events associated with this therapy (or with the use of placebo) were reported. Table 3 summarizes characteristics of the patients who experienced AAD. Compared with the placebo, S. boulardii significantly reduced the risk of diarrhoea caused by oral amoxicillin in combination with clavulanate, and intravenous cefuroxime. 
RESULTS
Characteristics and outcome measures
Investigation of the potential effects of missing responses
Assuming all patients in both groups with an unknown outcome to have had either a good or a poor outcome, our results demonstrate a significant difference in outcomes between the two treatments. Assuming extreme case favouring of S. boulardii (i.e. all of the patients with an unknown outcome in the placebo group and none of the patients in the S. boulardii group had diarrhoea or AAD) gave similar results. The only exception was upon assuming (the unlikely) extreme case favouring of placebo (i.e. all of the patients with an unknown outcome in the S. boulardii group and none of the patients in the placebo group had diarrhoea or AAD), which showed no significant difference between the groups.
DISCUSSION
To our knowledge, this is the first RCT to assess the effectiveness of S. boulardii in preventing AAD in children. Consistent with previous findings in adults, 15 we found that S. boulardii (250 mg twice daily) is effective in preventing AAD in children treated with antibiotics for otitis media and/or respiratory tract infections. For every eight patients receiving daily S. boulardii with antibiotics, one fewer will develop AAD. The risk of C. difficile diarrhoea was lower in our group of children receiving S. boulardii compared with placebo, however, the difference was of borderline significance.
This is also one of the few trials to evaluate potential important consequences of AAD (e.g. need for discontinuation of antibiotic treatment, hospitalization or intravenous rehydration). Despite rather conservative definition of diarrhoea used in this trial ( ‡3 loose or watery stools per day for a minimum of 48 h), no diarrhoeal episodes required hospitalization of outpatients or additional treatment. The mechanism by which S. boulardii exerts its action in preventing AAD is unclear. Possible mechanisms, which have been demonstrated in animals, include the production of a protease that inactivates the toxin A receptor, the production of increased levels of secretory IgA and IgA antitoxin A and competition for attachment sites. [22] [23] [24] Saccharomyces boulardii has also been shown to block C. difficile adherence to cells in vitro.
25
The consistency of the results obtained with S. boulardii in the paediatric (this study) and adult (prior reports) populations is noteworthy given the conflicting results from RCTs evaluating the efficacy of another probiotic strain, Lactobacillus GG. Whereas co-administration of Lactobacillus GG (with antimicrobials) reduced both the incidence and duration of associated diarrhoea in two RCTs involving children, 18, 19 it failed to prevent diarrhoea in a large study of hospitalized adults. 17 Potential reasons for these conflicting results include the use of lower dosages of probiotics in adults, differences in the administered antibiotics, and/or age-related differences in the pathogenesis of AAD. The design of this study does not allow conclusions about the efficacy of S. boulardii in preventing diarrhoea attributable to any single antibiotic class. However, our result suggests that S. boulardii effectively prevents diarrhoea caused by amoxicillin in combination with clavulanate as well as intravenously administered cefuroxime. Larger trials will be necessary to further address these issues.
Patients were only followed up for 2 weeks after their antibiotic treatment. As diarrhoea may occur up to 2 months after the end of such treatment, some cases of AAD may have been missed. Also, because we only evaluated the presence of major enteropathogens in diarrhoeal stool samples, one cannot exclude the possibility that some of the cases of unexplained diarrhoea were caused by unidentified infectious agents. Thus, AAD as defined in this study should be considered of possible, rather than of obvious, antibiotic origin.
In our study, Saccharum lactis was used as a placebo.
As data regarding the reliability of routine tests for diagnosing lactose malabsorption in children are scarce, 26 no specific tests were performed to exclude lactase deficiency. However, we did obtain a detailed history of acute/chronic diarrhoea, as well as any chronic gastrointestinal diseases, in each patient. Thus, we believe it is unlikely that there were any unrecognized cases of lactose malabsorption contributing to the diarrhoea. Furthermore, the double-blind randomized design and large number of participants represent compensatory strengths of our study. Although our study shows that S. boulardii may be useful in preventing AAD, it provides little support for a role of S. boulardii in its treatment. Further, RCTs are needed to explore this issue as well as potential treatment complications. Whereas no adverse effects were observed in our study, the administration of S. boulardii is not without risk. Almost 30 case reports of S. boulardii fungaemia exist in the literature. [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] Most complications have occurred in immunocompromised subjects or in patients with other life-threatening illnesses.
CONCLUSION
Results from this prospective RCT support the use of S. boulardii as adjunctive treatment in children undergoing antibiotic therapy for otitis media and/or respiratory tract infections. The likely advantages of probiotic co-administration with antibiotics include ease of administration and potential cost benefits. Yet some issues need to be resolved before widespread use of probiotics is advocated, including how to identify populations at high risk for AAD. In addition, future trials should address the efficacy of S. boulardii in preventing AAD in children caused specifically by C. difficile or those antibiotics that are most likely to cause diarrhoea, as well as the effectiveness of S. boulardii in treating AAD in children.
